Chris Liang

1.9k total citations
36 papers, 1.1k citations indexed

About

Chris Liang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chris Liang has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Chris Liang's work include Lung Cancer Treatments and Mutations (17 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Cancer Mechanisms and Therapy (9 papers). Chris Liang is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Cancer Mechanisms and Therapy (9 papers). Chris Liang collaborates with scholars based in United States, China and United Kingdom. Chris Liang's co-authors include Christine M. Lovly, Cho Tang, William Pao, Xueyan Wang, James Cheng‐Chung Wei, Anand Sistla, Yong Zhou, Hui Chen, Flora Tang and Asaad Nematalla and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Chris Liang

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chris Liang United States 13 581 479 463 239 125 36 1.1k
Jeffrey H. Chen United States 6 1.0k 1.7× 353 0.7× 520 1.1× 361 1.5× 207 1.7× 7 1.6k
Sharon K. Rudolph United States 9 497 0.9× 264 0.6× 312 0.7× 207 0.9× 97 0.8× 12 966
G. Dark United Kingdom 14 558 1.0× 334 0.7× 476 1.0× 225 0.9× 265 2.1× 28 1.4k
Anna Fioravanti Italy 21 326 0.6× 192 0.4× 395 0.9× 81 0.3× 134 1.1× 38 896
Kazuhide Nakamura Japan 18 601 1.0× 132 0.3× 249 0.5× 159 0.7× 130 1.0× 27 1.0k
Haitian Quan China 17 492 0.8× 383 0.8× 662 1.4× 188 0.8× 137 1.1× 30 1.3k
Toshiyuki Isoe Japan 16 623 1.1× 145 0.3× 385 0.8× 159 0.7× 110 0.9× 30 935
Teresa Di Desidero Italy 24 421 0.7× 253 0.5× 542 1.2× 45 0.2× 200 1.6× 52 1.1k
Suzanne Leijen Netherlands 13 770 1.3× 93 0.2× 728 1.6× 227 0.9× 98 0.8× 19 1.3k
Yanmei Xu China 9 736 1.3× 143 0.3× 528 1.1× 65 0.3× 194 1.6× 21 1.0k

Countries citing papers authored by Chris Liang

Since Specialization
Citations

This map shows the geographic impact of Chris Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Liang more than expected).

Fields of papers citing papers by Chris Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Liang. The network helps show where Chris Liang may publish in the future.

Co-authorship network of co-authors of Chris Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Liang. A scholar is included among the top collaborators of Chris Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Liang. Chris Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lü, Fang, Xiaoxin Li, Hong Dai, et al.. (2023). Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study. Eye. 37(15). 3228–3233. 4 indexed citations
2.
Liang, Chris, et al.. (2022). Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity. Molecular Therapy — Oncolytics. 24. 577–584. 19 indexed citations
3.
Bagegni, Nusayba A., Haeseong Park, Feng Gao, et al.. (2022). Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 89(4). 487–497. 7 indexed citations
4.
Pedersen, Katrina S., Patrick Grierson, Joel Picus, et al.. (2021). Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study. Investigational New Drugs. 39(5). 1298–1305. 25 indexed citations
5.
Song, Yan, Jinwan Wang, Xiubao Ren, et al.. (2021). Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chinese Journal of Cancer Research. 33(1). 103–114. 3 indexed citations
6.
Horn, Leora, Jeffrey R. Infante, Karen L. Reckamp, et al.. (2018). Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research. 24(12). 2771–2779. 131 indexed citations
7.
Scarpelli, M, Murtuza Rampurwala, Jens C. Eickhoff, et al.. (2018). Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemotherapy and Pharmacology. 82(2). 211–219. 6 indexed citations
8.
Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2017). P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 12(1). S1159–S1159. 5 indexed citations
9.
Jackson, Timothy L., David S. Boyer, David M. Brown, et al.. (2017). Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology. 135(7). 761–761. 34 indexed citations
10.
Horn, Leora, Yi‐Long Wu, Martin Reck, et al.. (2017). eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 35(15_suppl). TPS8578–TPS8578. 5 indexed citations
11.
Wakelee, Heather A., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC. Journal of Thoracic Oncology. 11(10). S209–S210. 3 indexed citations
12.
Horn, Leora, Heather A. Wakelee, Karen L. Reckamp, et al.. (2016). MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC. Journal of Thoracic Oncology. 11(11). S256–S257. 7 indexed citations
13.
Reckamp, Karen L., Jeffrey R. Infante, George R. Blumenschein, et al.. (2016). Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 11(2). S36–S37. 8 indexed citations
14.
Shu, Mengjun, Yaqing Chen, Qun He, et al.. (2014). A novel lead compound CM-118. Cancer Biology & Therapy. 15(6). 721–734. 12 indexed citations
15.
Wang, Xiang, Xi Zhang, Benshang Li, et al.. (2014). Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia. Oncotarget. 5(21). 10732–10744. 11 indexed citations
16.
Liang, Chris, David Brown, Nauman Chaudhry, Michael J. Elman, & Jeffrey S. Heier. (2013). Rationale for Treating Wet AMD in Human Using an Oral Pill Consisting of a VEGFR/PDGFR Inhibitor X-82. Investigative Ophthalmology & Visual Science. 54(15). 3272–3272. 1 indexed citations
17.
Liu, Jiali, et al.. (2012). Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR. Biochemical Pharmacology. 83(9). 1183–1194. 16 indexed citations
18.
Lovly, Christine M., Johannes M. Heuckmann, Elisa de Stanchina, et al.. (2011). Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors. Cancer Research. 71(14). 4920–4931. 177 indexed citations
19.
20.
Laird, Alexander, et al.. (2003). Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 14(1). 187–190. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey H. Chen Breakdown of academic impact, for papers by Sharon K. Rudolph Breakdown of academic impact, for papers by G. Dark Breakdown of academic impact, for papers by Anna Fioravanti Breakdown of academic impact, for papers by Kazuhide Nakamura Breakdown of academic impact, for papers by Haitian Quan Breakdown of academic impact, for papers by Toshiyuki Isoe Breakdown of academic impact, for papers by Teresa Di Desidero Breakdown of academic impact, for papers by Suzanne Leijen Breakdown of academic impact, for papers by Yanmei Xu
Rankless by CCL
2026